BCR
Basic information
Region (hg38): 22:23179704-23318037
Previous symbols: [ "D22S11", "BCR1" ]
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
CML treatment, response to | AD | Pharmacogenomic | Variants may confer resistance to certain medications (eg, dasatinib); Certain variants appear to confer STI571 resistance in CML treatment | General | 11423618; 12654249; 14534339; 17684099 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the BCR gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 22 | 10 | 33 | |||
missense | 68 | 78 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 2 | 6 | 8 | |||
non coding | 6 | |||||
Total | 0 | 0 | 71 | 33 | 15 |
Variants in BCR
This is a list of pathogenic ClinVar variants found in the BCR region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
22-23180998-C-G | not specified | Uncertain significance (Mar 18, 2024) | ||
22-23181068-G-T | not specified | Uncertain significance (Feb 26, 2024) | ||
22-23181098-G-T | Benign (Dec 31, 2019) | |||
22-23181121-T-C | not specified | Uncertain significance (Nov 07, 2024) | ||
22-23181122-C-T | Benign (Aug 17, 2018) | |||
22-23181165-A-G | not specified | Uncertain significance (Oct 21, 2024) | ||
22-23181169-A-G | not specified | Uncertain significance (May 23, 2023) | ||
22-23181174-C-T | not specified | Uncertain significance (Dec 17, 2023) | ||
22-23181176-G-T | Likely benign (May 24, 2018) | |||
22-23181192-C-T | not specified | Uncertain significance (Jan 03, 2022) | ||
22-23181199-C-T | not specified | Uncertain significance (Sep 22, 2023) | ||
22-23181220-C-G | not specified | Uncertain significance (Dec 17, 2021) | ||
22-23181241-C-T | not specified | Uncertain significance (Jul 17, 2023) | ||
22-23181264-G-C | not specified | Uncertain significance (Oct 29, 2024) | ||
22-23181270-G-A | not specified | Uncertain significance (Aug 03, 2022) | ||
22-23181304-C-T | not specified | Uncertain significance (May 03, 2023) | ||
22-23181321-G-T | not specified | Uncertain significance (Aug 27, 2024) | ||
22-23181353-C-A | Likely benign (Jul 01, 2022) | |||
22-23181355-G-C | Likely benign (Apr 10, 2018) | |||
22-23181355-G-T | not specified | Uncertain significance (Dec 28, 2022) | ||
22-23181414-G-A | not specified | Uncertain significance (Sep 07, 2022) | ||
22-23181415-C-T | Benign (Feb 01, 2024) | |||
22-23181457-G-A | Benign (Aug 08, 2018) | |||
22-23181460-A-C | not specified | Uncertain significance (Feb 05, 2024) | ||
22-23181512-C-A | not specified | Uncertain significance (Nov 14, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
BCR | protein_coding | protein_coding | ENST00000305877 | 23 | 138334 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.988 | 0.0124 | 125726 | 0 | 18 | 125744 | 0.0000716 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.888 | 685 | 754 | 0.909 | 0.0000469 | 8218 |
Missense in Polyphen | 120 | 179.41 | 0.66884 | 1860 | ||
Synonymous | -1.91 | 370 | 326 | 1.13 | 0.0000221 | 2449 |
Loss of Function | 5.79 | 10 | 57.4 | 0.174 | 0.00000263 | 679 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000518 | 0.000460 |
Ashkenazi Jewish | 0.000202 | 0.000198 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000865 | 0.0000462 |
European (Non-Finnish) | 0.0000449 | 0.0000440 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity. {ECO:0000269|PubMed:1657398, ECO:0000269|PubMed:1903516}.;
- Disease
- DISEASE: Leukemia, chronic myeloid (CML) [MIM:608232]: A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts. {ECO:0000269|PubMed:2407300, ECO:0000269|PubMed:3107980, ECO:0000269|PubMed:3540951}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Note=A chromosomal aberration involving BCR has been found in patients with chronic myeloid leukemia. Translocation t(9;22)(q34;q11) with ABL1. The translocation produces a BCR-ABL found also in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). {ECO:0000269|PubMed:3107980, ECO:0000269|PubMed:7665185}.;
- Pathway
- Chronic myeloid leukemia - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Imatinib Pathway, Pharmacokinetics/Pharmacodynamics;Imatinib and Chronic Myeloid Leukemia;Disease;Signal Transduction;inhibition of cellular proliferation by gleevec;integrin signaling pathway;bcr signaling pathway;ctcf: first multivalent nuclear factor;Rho GTPase cycle;Signaling by Rho GTPases;Regulation of RAC1 activity;Signaling by FGFR in disease;Signaling by cytosolic FGFR1 fusion mutants;FGFR1 mutant receptor activation;Signaling by FGFR1 in disease;Diseases of signal transduction;Regulation of RhoA activity
(Consensus)
Recessive Scores
- pRec
- 0.764
Intolerance Scores
- loftool
- 0.144
- rvis_EVS
- -1.25
- rvis_percentile_EVS
- 5.36
Haploinsufficiency Scores
- pHI
- 0.279
- hipred
- Y
- hipred_score
- 0.816
- ghis
- 0.515
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- K
- gene_indispensability_pred
- E
- gene_indispensability_score
- 1.00
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Bcr
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; digestive/alimentary phenotype; immune system phenotype; renal/urinary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype;
Gene ontology
- Biological process
- negative regulation of cellular extravasation;renal system process;protein phosphorylation;signal transduction;brain development;peptidyl-tyrosine phosphorylation;actin cytoskeleton organization;regulation of Rho protein signal transduction;intracellular signal transduction;inner ear morphogenesis;regulation of vascular permeability;negative regulation of neutrophil degranulation;positive regulation of GTPase activity;protein autophosphorylation;platelet-derived growth factor receptor signaling pathway;homeostasis of number of cells;negative regulation of inflammatory response;positive regulation of phagocytosis;modulation of chemical synaptic transmission;neuromuscular process controlling balance;regulation of small GTPase mediated signal transduction;regulation of nitrogen compound metabolic process;regulation of cell cycle;definitive hemopoiesis;negative regulation of respiratory burst;negative regulation of blood vessel remodeling;intracellular protein transmembrane transport;cellular response to lipopolysaccharide;negative regulation of reactive oxygen species metabolic process
- Cellular component
- cytosol;postsynaptic density;membrane;cell junction;protein-containing complex;postsynaptic membrane;extracellular exosome;Schaffer collateral - CA1 synapse;glutamatergic synapse;postsynaptic density, intracellular component
- Molecular function
- protein serine/threonine kinase activity;protein tyrosine kinase activity;Rho guanyl-nucleotide exchange factor activity;GTPase activator activity;protein binding;ATP binding;kinase activity